Assessment of suitable Antihypertensive therapies: Combination with high dose amlodipine/Irbesartan vs. triple combination with amlodipine/Irbesartan/Indapamide
- Conditions
- Hypertension
- Registration Number
- JPRN-UMIN000013343
- Lead Sponsor
- Asahikawa Medical University
- Brief Summary
High-dose CCBs combined with ARBs and a triple combination with diuretics combined with standard-dose CCB/ARBs produced a similar efficacy in reducing the BP. Both combination therapies can be used safely and effectively in hypertensive patients uncontrolled by standard doses of ARBs and CCBs.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 94
Not provided
1) Patients with secondary hypertension 2) Patients with a history of severe renal disease: serum creatinine>2.0 mg/dl 3) Patients with critical liver damage (AST or ALT>100 IU/l) 4) Patients with a history of adverse effects to ARBs 5) Bilateral renal artery stenosis 6) Patients with hyperkalemia >=5.5 mEq/L 7) Patients with pregnancy or breast-feeding 8) Patients with a poor prognosis such as a malignant tumor 9) Patients who are considered not to be eligible for the study by the investigator due to medical reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Systolic/Diastolic blood pressure change after a 12 week treatment
- Secondary Outcome Measures
Name Time Method Blood pressure change (home blood pressure monitoring in the morning and at night) Change in the ambulatory blood pressure (ABPM) The rate of achieving the target blood pressure Change in the laboratory data Systolic/Diastolic blood pressure change after a 24 week treatment The rate of continued treatment and the compliance of the treatment at 24 weeks